Topic: inflammatory bowel disease
Drug materials are targets of U.S.-China trade war, analysts see more hope in the Takeda-Shire deal, China puts forward policies that favors generics over brands.
The departure of Celgene COO Scott Smith wasn't entirely surprising, given recent setbacks, including a delayed FDA decision on the company's MS candidate ozanimod.
A new disease awareness campaign from Daiichi Sankyo highlights iron deficits common in patients with Crohn’s disease and ulcerative colitis.
Takeda has rolled out Entyvio in multiple Asia-Pacific countries, but the Japanese drugmaker envisions even more growth in the region.
Takeda and Cedars Sinai researchers developed an online tool aimed at helping inflammatory bowel disease patients sort through available treatments.
Anti-TNFs have been running the table in inflammatory bowel disease, but that’s changing. And as it does, the market’s primed for a big expansion.
Takeda’s IBD awareness comic book campaign, a team-up with Marvel, ended with the Unbeatables prevailing over IBD—and evildoers, too.
The FDA served a Mylan plant with a warning letter, Takeda inked a microbiome GI deal with NuBiyota and China works on new trial data fabrication policies.
Gilead is planning its first foreign manufacturing facility, Takeda will develop an IBD drug from Finch while cutting 180 workers at Ariad after the buyout.